These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

benzinga.com/analyst-stock-ratings/price-target/25/06/45982320/these-analysts-revise-their-forecasts-on-sage-therapeutics-following-acquisiti

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ:SAGE) for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561…

This story appeared on benzinga.com, 2025-06-17 18:22:48.
The Entire Business World on a Single Page. Free to Use →